Gram-positive infections: Lessons learnt and novel solutions

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 8, 2006, Pages 3-8

  Finch, R ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Drug resistance; Gram positive bacteria; Methicillin resistance; Staphylococcus aureus

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ICLAPRIM; LINEZOLID; MACROLIDE; METICILLIN; MINOCYCLINE; ORITAVANCIN; OXACILLIN; OXAZOLIDINONE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TELITHROMYCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AUTHORITY; BACTERIAL INFECTION; CONFERENCE PAPER; ENDEMIC DISEASE; GRAM POSITIVE BACTERIUM; HEALTH PROGRAM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; THERAPY EFFECT;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 33750737310     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01624.x     Document Type: Conference Paper

References (50)

1. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005; 55 (suppl 2): Ii5-ii13.
2. Barrett JF. Recent developments in glycopeptide antibacterials. Curr Opin Invest Drugs 2005; 6: 781-790.
3. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005; 11 (suppl 3): 22-28.
4. Tenover FC, Lancaster MV, Hill BC et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-1027.
5. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1: 57-58.
6. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System Report data summary from January 1992 through June 2004. 2004. http://www.cdc.gov/ncidod/dhqp/pdf/nnis/ 2004NNISreport.pdf (accessed 11 October 2006).
7. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2004. http://www.rivm.nl/earss/Images/ EARSS%20annual%20report%202004%20webversie_tcm61-25345.pdf (accessed 11 October 2006).
8. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003; 51 (suppl 3): Iii23-iii30.
9. Montecalvo MA, Horowitz H, Gedris C et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38: 1363-1367.
10. Malathum K, Murray BE. Vancomycin-resistant enterococci: Recent advances in genetics, epidemiology and therapeutic options. Drug Resist Update 1999; 2: 224-243.
11. Landman D, Quale JM. Management of infections due to resistant enterococci: A review of therapeutic options. J Antimicrob Chemother 1997; 40: 161-170.
12. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus: Pennsylvania, 2002. MMWR 2002; 51: 902.
13. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin. MMWR 2002; 51: 565-567.
14. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2000; 19: 403-417.
15. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: Report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002; 43: 65-73.
16. Raad I, Alrahwan A, Rolston K. Staphylococcus epidermidis: Emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26: 1182-1187.
17. Barrett JF. MRSA-what is it, and how do we deal with the problem? Expert Opin Ther Targets 2005; 9: 253-265.
18. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5: 9-17.
19. Kim T, Oh MD, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001; 22: 99-104.
20. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs? Infect Control Hosp Epidemiol 1999; 20: 408-411.
21. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging pathogen. Infect Control Hosp Epidemiol 2003; 24: 451-455.
22. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: A review. Pharmacotherapy 2005; 25: 74-85.
23. Adhikari RP, Cook GM, Lamont I, Lang S, Heffernan H, Smith JM. Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2002; 50: 825-831.
24. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect 1993; 25: 97-108.
25. Okuma K, Iwakawa K, Turnidge JD et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40: 4289-4294.
26. Eguia JM, Chambers HF. Community-acquired methicillin-resistant Staphylococcus aureus. Epidemiology and potential virulence factors. Curr Infect Dis Rep 2003; 5: 459-466.
27. An Diep B, Sensabaugh GF, Somboona NS, Carleton HA, Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol 2004; 42: 2080-2084.
28. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005; 41 (suppl 4): S269-S272.
29. Boyle-Vavra S, Ereshefsky B, Wang CC, Daum RS. Successful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV. J Clin Microbiol 2005; 43: 4719-4730.
30. Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: Current perspectives. Clin Microbiol Infect 2006; 12 (suppl 1): 9-15.
31. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-139.
32. Gosbell IB, Mercer JL, Neville SA et al. Non-multiresistant and multiresistant methicillin-resistant Staphylococcus aureus in community-acquired infections. Med J Aust 2001; 174: 627-630.
33. O'Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak. J Clin Microbiol 1999; 37: 2858-2862.
34. Maguire GP, Arthur AD, Boustead PJ, Dwyer B, Currie BJ. Clinical experience and outcomes of community-acquired and nosocomial methicillin-resistant Staphylococcus aureus in a northern Australian hospital. J Hosp Infect 1998; 38: 273-281.
35. Harbarth S, Francois P, Shrenzel J et al. Community-associated methicillin-resistant Staphylococcus aureus, Switzerland. Emerg Infect Dis 2005; 11: 962-965.
36. Naas T, Fortineau N, Spicq C, Robert J, Jarlier V, Nordmann P. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital. J Hosp Infect 2005; 61: 321-329.
37. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance System (NNIS). 2005. http://www.cdc.gov/ncidod/ dhqp/nnis.html (accessed 11 October 2006).
38. Centres for Disease Control and Prevention. Antimicrobiol Resistance in Healthcare Settings. 2005. http://www.cdc.gov/ncidod/dhqp/ar.html (accessed 11 Otcober 2006).
39. Department of Health United Kingdom. Specialist Advisory Committee on Antimicrobial Resistance (SACAR). 2006. http://www.advisorybodies.doh.gov.uk/sacar/ (accessed 11 October 2006).
40. National Health and Medical Research Council of Australia. Expert Advisory Group on Antimicrobial Resistance (EAGAR). 2006. http://www.nhmrc.gov.au/about/committees/expert/eagar/index.htm (accessed 11 October 2006).
41. Ekdahl K. Perspectives on containing antimicrobial resistance-ways to go. 2005. http://www.ecdc.eu.int/pdf/Future-perspectives-AMR.pdf (accessed 11 October 2006).
42. Gould IM. Control of methicillin-resistant Staphylococcus aureus in the UK. Eur J Clin Microbiol Infect Dis 2005; 24: 789-793.
43. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
44. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis 2006; 42 (suppl 1): S51-S57.
45. Shah PM. The need for new therapeutic agents: What is the pipeline? Clin Microbiol Infect 2005; 11 (suppl 3): 36-42.
46. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-4672.
47. Tedesco KL, Rybak MJ. Daptomycin. Pharmacotherapy 2004; 24: 41-57.
48. Fowler VG Jr, Broucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665.
49. Wilcox MH. Update on linezolid: The first oxazolidinone antibiotic. Expert Opin Pharmacother 2005; 6: 2315-2326.
50. Tran MP. Telithromycin: A novel agent for the treatment of community-acquired upper respiratory infections. Proc Bayl Univ Med Cent 2004; 17: 475-479.